Tuesday broker round-up UPDATE
8th Apr 2014 09:18
API Group: Numis lowers target price from 90p to 84p, while upgrading from add to buy. Cranswick: Investec increases target price from 1315p to 1390p retaining its buy recommendation. Daisy Group: FinnCap moves target price from 175p to 185p and retains a hold recommendation. DP World: Nomura rai
Read moreTuesday broker round-up UPDATE
1st Apr 2014 09:39
African Barrick Gold: Deutsche Bank raises target price from 240p to 310p and keeps a hold recommendation. African Minerals: Deutsche Bank lowers target price from 399p to 382p, while its buy recommendation is kept. Allergy Therapeutics: Panmure Gordon ups target price from 16p to 25p and retains
Read moreVernalis beats full-year targets, positive on outlook
1st Apr 2014 07:52
- Full-year ahead of expectations - Cold programme progressing well - Extremely positive outlook for 2014 and beyond Biotech specialist Vernalis said its full-year performance was ahead of market expectations and the outlook for 2014 and beyond is 'extremely positive'. The pharmaceutical company
Read moreN+1 Singer remains upbeat on Vernalis
24th Feb 2014 12:59
Broker N+1 Singer reiterated buy on biotech specialist Vernalis after the group hailed the successful completion of a final comparative bioavailability study for CCP-01, its promising long-acting prescription cough cold medicine for the US market. N+1 Singer Analyst, Dr Jens Lindqvist, said that t
Read moreWednesday broker round-up UPDATE
29th Jan 2014 08:54
African Barrick Gold: Canaccord Genuity ups target price from 180p to 205p keeping a hold recommendation. Antofagasta: Westhouse Securities takes target price from 1000p to 1060p and maintains its buy recommendation. BG Group: Liberum Capital reduces target price from 1475p to 1280p downgrading to
Read moreAdvanced Oncotherapy CEO makes triple purchase
26th Apr 2013 15:09
The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p
Read morePolymetal International Chief buys 100,000 shares
19th Apr 2013 08:12
The Chief Executive Officer of Polymetal International has purchased 713,750 pounds-worth of shares, just two days after the FTSE 100 mining group reported that the Mayskoye mine in Russia had produced its first dry gold concentrate. Vitaly Nesis celebrated the news with the purchase of 100,000 sh
Read moreVernalis receives 1.5m dollar payment through Genentech collaboration
4th Feb 2013 12:13
AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group. The collaboration, which commenced in January 2012, aims to discover novel small molecules against an undisclosed target utilising Vern
Read moreVernalis announces positive results for Parkinson's disease treatment study
12th Dec 2012 10:42
AIM-listed pharmaceutical company Vernalis has published positive results for a study of potential applications for Parkinson's disease and other central nervous system indications. The study examined the effects of V81444, its "A2A antagonist", on brain function. The study demonstrated that full
Read moreVernalis's first half revenues jump
1st Aug 2012 10:52
Vernalis, a development stage pharmaceutical company, saw first half losses halve on the back of a sharp rise in revenues, driven by a significant increase in collaboration income. Loss for the period was slashed to £3.2m (2011: £7.0m) on revenues of £5.9m, up 365 from £4.3m for the same period the
Read moreVernalis up as Parkinson's drug passes safety trial
2nd May 2012 11:13
The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease. The double-blind, placebo-controlled study showed "a wide range of doses were found to be well tolerated with no unexpected saf
Read moreWednesday tips round-up: Ryanair, LSE, Vernalis
4th Apr 2012 07:09
Questor, in the Telegraph, gives some quite clear advice on Ryanair: sell. The shares have risen 78% since the first tip back in 2009 and the oil price could make things difficult for the airlines in 2012. Time to get out and take profits, the paper recommends. In the Times, Tempus likes the Lond
Read moreMarket backs transformational Vernalis deal
10th Feb 2012 11:16
Shares in Vernalis, a UK pharmaceuticals company, were marked up after the company said it has placed shares at a premium to fund a drug development programme in combination with privately held US firm Tris Pharma. The company has placed 50m new shares, representing around 50% of the existing share
Read moreVernalis pleased with tests on new drug
28th Sep 2011 09:55
Shares in Vernalis rose this morning after the pharmaceutical firm said tests on its new painkiller had so far proved successful. The firm said that its Phase 1 trial of 'V158866' - a 'fatty acid amide hydrolase inhibitor' - had seen positive results following studies on male volunteers, pushing sh
Read moreSector movers: Falling metals prices pressures mining sector lower
12th Apr 2011 14:18
The miners are on the decline Tuesday, helped lower by the falling metals prices. Copper and gold futures have fallen as the escalating crisis in Japan has bought about concerns over demand. Mining titans Kazakhmys, Eurasian Natural Resources Corp, Anglo American, Antofagasta and Fresnillo are all
Read more